Smiths Group PLC
25 April 2006
Smiths wins five year Department of Defense contract to provide Chemical
Biological Protective Shelters
Multi-million Dollar Revenues Expected from CBPS-M3, Designed to Provide
Contamination Free, Environmentally Controlled Working Area for Medical, Combat
Services and Combat Service Support Personnel
Smiths Detection, part of the global engineering business Smiths Group, today
announced its Military unit has been awarded a contract to build Chemical
Biological Protective Shelters, Model 3 (CBPS-M3) for the U.S. Department of
Defense. CBPS-M3 is a highly mobile, self contained collective protection system
that provides a contamination free, environmentally controlled working area for
medical, combat services, and combat service support personnel to work freely
without continuously wearing chemical-biological protective clothing.
An initial contract has been received from U.S. Army TACOM Life Cycle Management
Command, Rock Island, valued at more than $10 million, that includes delivery of
21 systems, along with an initial test program. Annual revenue expectations are
around $25 million for Smiths Detection, dependant on Department of Defense
budget approvals, with additional revenue expected for global defence markets.
Over the 5-year contract period, the program has a total maximum contract
ceiling of $333 million.
'These Chemical Biological Protective Shelters are unique systems integrating
multiple levels of chemical-biological security in order to protect and equip
committed U.S. troops,' said Stephen Phipson, Group Managing Director of Smiths
Detection. 'The CBPS program represents a large-scale U.S. military
chemical-biological defence opportunity and will allow Smiths to continue
expansion of its presence beyond its sensor-centric markets to a vehicle system
integration program within Smiths' field of expertise.'
Smiths Group
Smiths is a global engineering business, listed on the London Stock Exchange.
Smiths focuses on high performance applications, building and sustaining
market-leading businesses in growth sectors. It reaches deep into global markets
taking its manufacturing closer to its customers. Smiths has four divisions:
Aerospace, Detection, Medical and Specialty. It employs 32,000 people and has
over 250 major facilities in 50 countries. For more information visit
www.smiths-group.com
Smiths Detection
Smiths Detection is one of four operating divisions of Smiths Group. Smiths
Detection offers technologically advanced security solutions to detect and
identify explosives, chemical and biological agents, weapons and contraband.
Employing trace detection technology together with Smiths-Heimann x-ray imaging,
Smiths Detection provides security solutions for customers in homeland security
and defence markets worldwide. For more information visit:
www.smithsdetection.com
-o-
Media: Investors:
Chris Fox Russell Plumley
+44 (0) 20 8457 8403 +44 (0) 20 8457 8203
chris.fox@smiths-group.com russell.plumley@smiths-group.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.